Prudence R Carr1, Lina Jansen1, Viola Walter1, Matthias Kloor2, Wilfried Roth3, Hendrik Bläker4, Jenny Chang-Claude5, Hermann Brenner6, Michael Hoffmeister7. 1. Divisions of Clinical Epidemiology and Aging Research. 2. Departments of Applied Tumor Biology and. 3. Unit of Molecular Tumor Pathology; and Pathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany; and. 4. Institute of Pathology, Charité University Medicine, Berlin, Germany. 5. Cancer Epidemiology, and. 6. Divisions of Clinical Epidemiology and Aging Research, Preventive Oncology; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; 7. Divisions of Clinical Epidemiology and Aging Research, m.hoffmeister@dkfz.de.
Abstract
BACKGROUND: Little is known about the prognostic impact of red and processed meat intake or about changes in consumption after a diagnosis of colorectal cancer (CRC). OBJECTIVES: We investigated associations of baseline red and processed meat with survival outcomes and explored changes in intake among CRC survivors 5 y after diagnosis. DESIGN: A total of 3122 patients diagnosed with CRC between 2003 and 2010 were followed for a median of 4.8 y [DACHS (Darmkrebs: Chancen der Verhütung durch Screening) study]. Patients provided information on diet and other factors in standardized questionnaires at baseline and at the 5-y follow-up. Cox proportional hazards regression models were used to estimate HRs and 95% CIs. RESULTS: Among patients with stage I-III CRC, baseline red and processed meat intake was not associated with overall (>1 time/d compared with <1 time/d; HR: 0.85; 95% CI: 0.67, 1.09), CRC-specific (HR: 0.83; 95% CI: 0.61, 1.14), cardiovascular disease-specific (HR: 0.92; 95% CI: 0.51, 1.68), non-CRC-specific (HR: 0.88; 95% CI: 0.59, 1.30), and recurrence-free (HR: 1.03; 95% CI: 0.80, 1.33) survival; results among stage IV patients were comparable. An association with worse overall survival was found among patients with Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutated CRC (HR: 1.99; 95% CI: 1.10, 3.56) but not with microsatellite instability or CpG island methylator phenotype (CIMP) positivity. A much lower proportion of survivors reported daily consumption of red and processed meat at the 5-y follow-up than at baseline (concordance rate: 39%; κ-value: 0.10; 95% CI: 0.07, 0.13). CONCLUSIONS: Our findings suggest that baseline red and processed meat intake is not associated with poorer survival among patients with CRC. The potential interaction with KRAS mutation status warrants further evaluation. Major changes in consumption measured at the 5-y follow-up may have had an impact on our survival estimates.
BACKGROUND: Little is known about the prognostic impact of red and processed meat intake or about changes in consumption after a diagnosis of colorectal cancer (CRC). OBJECTIVES: We investigated associations of baseline red and processed meat with survival outcomes and explored changes in intake among CRC survivors 5 y after diagnosis. DESIGN: A total of 3122 patients diagnosed with CRC between 2003 and 2010 were followed for a median of 4.8 y [DACHS (Darmkrebs: Chancen der Verhütung durch Screening) study]. Patients provided information on diet and other factors in standardized questionnaires at baseline and at the 5-y follow-up. Cox proportional hazards regression models were used to estimate HRs and 95% CIs. RESULTS: Among patients with stage I-III CRC, baseline red and processed meat intake was not associated with overall (>1 time/d compared with <1 time/d; HR: 0.85; 95% CI: 0.67, 1.09), CRC-specific (HR: 0.83; 95% CI: 0.61, 1.14), cardiovascular disease-specific (HR: 0.92; 95% CI: 0.51, 1.68), non-CRC-specific (HR: 0.88; 95% CI: 0.59, 1.30), and recurrence-free (HR: 1.03; 95% CI: 0.80, 1.33) survival; results among stage IV patients were comparable. An association with worse overall survival was found among patients with Kirsten ratsarcoma viral oncogene homolog (KRAS)-mutated CRC (HR: 1.99; 95% CI: 1.10, 3.56) but not with microsatellite instability or CpG island methylator phenotype (CIMP) positivity. A much lower proportion of survivors reported daily consumption of red and processed meat at the 5-y follow-up than at baseline (concordance rate: 39%; κ-value: 0.10; 95% CI: 0.07, 0.13). CONCLUSIONS: Our findings suggest that baseline red and processed meat intake is not associated with poorer survival among patients with CRC. The potential interaction with KRAS mutation status warrants further evaluation. Major changes in consumption measured at the 5-y follow-up may have had an impact on our survival estimates.
Authors: Prudence R Carr; Barbara L Banbury; Sonja I Berndt; Peter T Campbell; Jenny Chang-Claude; Richard B Hayes; Barbara V Howard; Lina Jansen; Eric J Jacobs; Dorothy S Lane; Reiko Nishihara; Shuji Ogino; Amanda I Phipps; Martha L Slattery; Marcia L Stefanick; Robert Wallace; Viola Walter; Emily White; Kana Wu; Ulrike Peters; Andrew T Chan; Polly A Newcomb; Hermann Brenner; Michael Hoffmeister Journal: Clin Gastroenterol Hepatol Date: 2018-11-23 Impact factor: 11.382
Authors: Sylvia H J Jochems; Frits H M Van Osch; Richard T Bryan; Anke Wesselius; Frederik J van Schooten; Kar Keung Cheng; Maurice P Zeegers Journal: BMJ Open Date: 2018-02-19 Impact factor: 2.692
Authors: Shailesh Mahesh Advani; Pragati Shailesh Advani; Derek W Brown; Stacia M DeSantis; Krittiya Korphaisarn; Helena M VonVille; Jan Bressler; David S Lopez; Jennifer S Davis; Carrie R Daniel; Amir Mehrvarz Sarshekeh; Dejana Braithwaite; Michael D Swartz; Scott Kopetz Journal: BMC Cancer Date: 2019-10-17 Impact factor: 4.430